Tissue imaging using MALDI (Matrix Assissted Laser Desorption Imaging) spectrometry, applied to biomolecules in histopathological material, can serve as a tool to discover new predictive biomarkers. Tissue imaging MALDI allows to determine the distribution of biomolecules and drugs in the tissue and can therefore be used to distinguish between benign and malignant tissues without the need for antibodies. In this technique, tissue sections are covered with a matrix layer and then the molecular weight of each tissue "pixel" point is measured. Depending on the tissue processing, lipids, proteins and metabolites can be profiled and the use of MALDI imaging enables the identification and distribution analysis of specific tissue biomarkers. Using this method, the proteins and peptides of canine adenocarcinoma, fibrosarcoma and benign tumors (adenomas and fibromas) were characterized, and proteins specific for neoplastic lesions and changes in their distribution were identified and can be used as predictive markers. In the future, the use of MALDI imaging for the histological evaluation of tissue will allow for faster and personalized diagnosis compared to classical immunohistochemistry.
We offer expertise in the field of mass spectrometry imaging and MS data processing, we are looking for research centers, hospitals and pharmaceutical companies to cooperate in the project to develop modern diagnostics of cancer using MALDI mass spectrometry imaging. Cooperation may involve participation in a joint scientific project and / or commercial contract with the company to develop a specific method. The development and validation of a panel of biomolecules characteristic for a given type of cancer will allow faster determination whether a biopsy sample is malignant, which will significantly shorten the waiting time for results, profiling MALDI imaging of cancer tissues will allow testing the impact of new therapies on cancer metabolism and allow determining the degree of drug penetration in tissue.
Meet the presenter: